ArticleMMWR. Morbidity and mortality weekly report2019
Novel Treatment of a Vaccinia Virus Infection from an Occupational Needlestick - San Diego, California, 2019.
Article in MMWR. Morbidity and mortality weekly report, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Integrating PrEP and Sexual Reproductive Health Services for Adolescent Girls and Young Women in South Africa: A Scoping Review.AIDS and behavior · 2026Review
- Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022-2023.NEJM evidence · 2024Article
- Article
- Interim Clinical Treatment Considerations for Severe Manifestations of Mpox - United States, February 2023.MMWR. Morbidity and mortality weekly report · 2023Article
- Clinical Manifestation, Transmission, Pathogenesis, and Diagnosis of Monkeypox Virus: A Comprehensive Review.Life (Basel, Switzerland) · 2023Review
- Antivirals With Activity Against Mpox: A Clinically Oriented Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Review
- Disease History, Pathogenesis, Diagnostics, and Therapeutics for Human Monkeypox Disease: A Comprehensive Review.Vaccines · 2022Review
- Monkeypox: epidemiology, pathogenesis, treatment and prevention.Signal transduction and targeted therapy · 2022Review
- Monkeypox: A Comprehensive Review.Viruses · 2022Review
- Unusual global outbreak of monkeypox: what should we do?Frontiers of medicine · 2022Review
- Monkeypox: A Contemporary Review for Healthcare Professionals.Open forum infectious diseases · 2022Review
- Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.MMWR. Morbidity and mortality weekly report · 2022Article
- Zika Virus Infection During Research Vaccine Development: Investigation of the Laboratory-Acquired InfectionFrontiers in cellular and infection microbiology · 2022Review
- The Disease Ecology, Epidemiology, Clinical Manifestations, Management, Prevention, and Control of Increasing Human Infections with Animal Orthopoxviruses.Wilderness & environmental medicine · 2021Review
- An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications.Expert review of anti-infective therapy · 2021Review
- Antivirals in medical biodefense.Virus genes · 2020Review
- Development of Improved Devices for Handling and Restraining Experimental Laboratory Mice.Applied biosafety : journal of the American Biological Safety Association · 2020Article
- A review of vaccines and antivirals against human poxviruses with special emphasis on mpox virus.Medical journal, Armed Forces IndiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccinia virus (VACV) is an orthopoxvirus used in smallpox vaccines, as a vector for novel cancer treatments, and for experimental vaccine research (1). The Advisory Committee on Immunization Practices (ACIP) recommends smallpox vaccination for laboratory workers who handle replication-competent VACV (1). For bioterrorism preparedness, the U.S. government stockpiles tecovirimat, the first Food and Drug Administration-approved antiviral for treatment of smallpox (caused by variola virus and globally eradicated in 1980*
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.